Golcadomide & RituximabA Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Sponsor:

Celgene

Code:

NCT06425302

Conditions

Lymphoma, Follicular

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Golcadomide

Rituximab

Cyclophosphamide

Doxorubicin

Vincristine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-26. This information was provided to ClinicalTrials.gov by Celgene on 2025-12-05.